Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Edan Diagnostics, LGC make deal for POC platform
December 2019
SHARING OPTIONS:

LONDON—Edan Diagnostics Inc., a wholly owned subsidiary of Edan Instruments Inc., has acquired LGC's ClariLight molecular diagnostics point-of-care (POC) platform, the companies announced recently. Included in this deal is a partnership with LGC to develop molecular diagnostic assays designed for ClariLight and the supply of necessary enzymes and oligonucleotides for manufacturing. Edan will develop, manufacture and market the instrument and test cartridges, and commercialize them through its distribution network, with an expected launch within two to three years.
 
Zhang Hao, Edan CEO, remarked, “We believe that this acquisition will jump-start our entry into the rapidly growing molecular diagnostic market. There is a growing need for this type of testing throughout the world. The opportunity to continue to work with LGC provides additional confidence that we will be able to launch our first products in this area as planned.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.